WHO consolidated guidelines on tuberculosis.2022 update
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delama...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Geneva, Switzerland :
World Health Organization
2022.
|
| Edición: | 1st ed |
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009757138106719 |
Tabla de Contenidos:
- Intro
- Acknowledgements
- Abbreviations and acronyms
- Definitions
- Executive summary
- Introduction
- Recommendations
- Section 1. The 6-month bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) regimen for MDR/RR-TB (NEW)
- Section 2. The 9-month all-oral regimen for MDR/RR-TB (NEW)
- Section 3. Longer regimens for MDR/RR-TB
- Section 4. Regimen for rifampicin-susceptible, isoniazid-resistant TB (Hr-TB)
- Section 5. Monitoring patient response to MDR/RR-TB treatment using culture
- Section 6. Starting antiretroviral therapy in patients on MDR/RR-TB regimens
- Section 7. Surgery for patients on MDR/RR-TB treatment
- Research gaps
- References
- Annex 1. Supplementary table
- Annex 2. Trial population in ZeNix and TB-PRACTECAL trials.
